13 September 2021
2 min read
Luxembourg rewarded for its translational medicine excellence
The EATRIS Luxembourg Node receives the Node Reward Framework award
In August 2021, the Luxembourg node of the European Research Infrastructure for Translational Medicine (EATRIS) network was granted the EATRIS Node Reward Framework award for its significant contribution to the efforts and impact of the European infrastructure in advancing translational medicine in 2020.
Through the EATRIS Node Reward Framework award, the EATRIS Luxembourg Node, coordinated by Luxembourg Institute of Health (LIH) and encompassing its Integrated Biobank of Luxembourg (IBBL) and the Luxembourg Centre for Systems Biomedicine (LCSB) of the University of Luxembourg, was rewarded for its achievements in terms of translational research. Specifically, the award recognised the remarkable efforts of the Luxembourg Node members with regard to the two flagship COVID-19 studies CON-VINCE and Predi-COVID, as well as the collaborative FNR-funded doctoral training programme i2TRON.
“The Luxembourg EATRIS institutes play a crucial role in establishing training programmes and clinical studies with a focus on translational science and personalised medicine. This excellence was particularly evident in 2020, when all research institutes in Luxembourg came together to rapidly and effectively respond to the COVID-19 pandemic, while pursuing their existing research activities”
says Dr Iris Egner, Clinical Research Project Manager at LIH and National Coordinator of the EATRIS Luxembourg Node.
“We are therefore extremely grateful to the EATRIS Board of Governors for the recognition of our collective efforts and for giving additional European visibility to the Luxembourg translational medicine ecosystem”
concludes Dr Frank Glod, Chief of Scientific Operations at LIH and National Director of the EATRIS Luxembourg Node.
The EATRIS Node Reward Framework award, which was concomitantly also granted to the Spain and Portugal Nodes, consists of an open grant of EUR 6,000 that can be used to finance further efforts in driving EATRIS growth, education & training, improving quality & reproducibility, or other activities that contribute to the activities and impact of EATRIS.